We are live on ! Find out more
OM

Opaleye Management Portfolio holdings

AUM $1.1B
1-Year Est. Return 197.64%
This Fund
S&P 500
This Quarter Est. Return
+6.78%
1 Year Est. Return
+197.64%
3 Year Est. Return
+748.31%
5 Year Est. Return
+1,163.14%
10 Year Est. Return
+87,953.69%
AUM
$150M
AUM Growth
-$10.7M
Cap. Flow
-$11.4M
Cap. Flow %
-7.61%
Top 10 Hldgs %
46.24%
Holding
65
New
12
Increased
10
Reduced
12
Closed
16
Avg Time Held
3.4 quarters
Top 10 Avg Time Held
2.2 quarters
Top 20 Avg Time Held
3.2 quarters

Top Buys

Rank Stock Value
1
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$3.24M
2
GBT
Global Blood Therapeutics, Inc.
GBT
+$3.07M
3
OCUL icon
Ocular Therapeutix
OCUL
+$2.58M
4
MGNX icon
MacroGenics
MGNX
+$2.53M
5
NGNE icon
Neurogene
NGNE
+$2.34M

Top Sells

Rank Stock Value
1
SAGE icon
Sage Therapeutics
SAGE
+$5.29M
2
ASRT icon
Assertio
ASRT
+$4.53M
3
GERN icon
Geron
GERN
+$3.87M
4
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$3.38M
5
RARE icon
Ultragenyx Pharmaceutical
RARE
+$2.91M

Sector Composition

Rank Sector Weight
1 Healthcare 91.89%
2 Miscellaneous 8.11%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
AXGN icon
1
Axogen
AXGN
$2.18B
$14.6M 9.74%
2,120,000
– –
2015 Q1
5 quarters
GNMX icon
2
DELISTED
Aevi Genomic Medicine Inc
GNMX
$10.8M 7.23%
1,950,000
+392,300
+25% +$2.06M
2014 Q4
6 quarters
ARIA
3
DELISTED
Ariad Pharmaceuticals Inc
ARIA
$9.24M 6.17%
1,250,000
– –
2013 Q4
10 quarters
KYNB icon
4
Kyntra Bio
KYNB
$24.8M
$5.42M 3.62%
13,200
+200
+2% +$91.6K
2014 Q4
6 quarters
BPMC icon
5
DELISTED
Blueprint Medicines
BPMC
$5.06M 3.38%
250,000
+30,000
+14% +$545K
2015 Q3
3 quarters
HROW icon
6
Harrow
HROW
$1.09B
$4.77M 3.18%
1,267,500
+17,500
+1% +$68.2K
2014 Q3
7 quarters
CDXS icon
7
Codexis
CDXS
$154M
$4.75M 3.17%
1,178,500
– –
2014 Q1
9 quarters
ADMS
8
DELISTED
Adamas Pharmaceuticals
ADMS
$4.54M 3.03%
300,000
-20,000
-6% -$330K
2015 Q1
5 quarters
FOMX
9
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$4.41M 2.95%
695,000
+105,000
+18% +$697K
2015 Q2
4 quarters
TVRD icon
10
Tvardi Therapeutics
TVRD
$14.1M
$4.02M 2.68%
23,194
-556
-2% -$121K
2014 Q4
6 quarters
AMRN icon
11
Amarin Corp
AMRN
$244M
$3.8M 2.54%
88,000
– –
2015 Q1
5 quarters
AGIO icon
12
Agios Pharmaceuticals
AGIO
$1.84B
$3.56M 2.38%
85,000
-20,000
-19% -$988K
2016 Q1
1 quarter
HZNP
13
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$3.29M 2.2%
+200,000
New +$3.24M
2016 Q2
0 quarters
RARE icon
14
Ultragenyx Pharmaceutical
RARE
$1.51B
$3.18M 2.12%
65,000
-45,000
-41% -$2.91M
2014 Q2
8 quarters
MGNX icon
15
MacroGenics
MGNX
$237M
$3.02M 2.02%
+112,000
New +$2.53M
2016 Q2
0 quarters
IMMU
16
DELISTED
Immunomedics Inc
IMMU
$3.02M 2.01%
1,300,000
-25,000
-2% -$83.5K
2015 Q4
2 quarters
INDP icon
17
Indaptus Therapeutics
INDP
$325M
$2.99M 2%
290
+5
+2% +$44.9K
2015 Q3
3 quarters
AMAG
18
DELISTED
AMAG Pharmaceuticals
AMAG
$2.87M 1.92%
120,000
-100,000
-45% -$2.29M
2015 Q1
5 quarters
CMRX icon
19
DELISTED
Chimerix, Inc.
CMRX
$2.65M 1.77%
675,000
– –
2016 Q1
1 quarter
SUPN icon
20
Supernus Pharmaceuticals
SUPN
$2.49B
$2.55M 1.7%
125,000
– –
2014 Q4
6 quarters
GBT
21
DELISTED
Global Blood Therapeutics, Inc.
GBT
$2.52M 1.68%
+152,000
New +$3.07M
2016 Q2
0 quarters
XENE icon
22
Xenon Pharmaceuticals
XENE
$3.47B
$2.42M 1.62%
410,000
+10,000
+3% +$68.6K
2015 Q3
3 quarters
PDSB icon
23
PDS Biotechnology
PDSB
$110M
$2.28M 1.52%
11,280
+2,030
+22% +$359K
2016 Q1
1 quarter
IOVA icon
24
Iovance Biotherapeutics
IOVA
$6.6B
$2.11M 1.41%
+260,000
New +$1.63M
2016 Q2
0 quarters
CYNA
25
DELISTED
CYNAPSUS THERAPEUTICS INC COM PAR NO PAR (CANADA)
CYNA
$2.09M 1.4%
125,000
+4,000
+3% +$53.8K
2015 Q3
3 quarters
1
2 3

Similar funds

CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
PFM
Premier Fund Managers Guildford, United Kingdom $1.1B AUM 14.42% 1-Year Est. Return
HBCM
Heron Bay Capital Management Bloomfield Hills, Michigan $1.1B AUM 11.31% 1-Year Est. Return
HAS
HBW Advisory Services Simi Valley, California $1.11B AUM 25.66% 1-Year Est. Return
AI
Aperture Investors New York $1.11B AUM 81.44% 1-Year Est. Return
TPA
Trivium Point Advisory Westport, Connecticut $1.1B AUM 28.81% 1-Year Est. Return
ZDA
Zweig-DiMenna Associates New York $1.1B AUM 171.86% 1-Year Est. Return
NW
Naviter Wealth Little Rock, Arkansas $1.1B AUM 33.28% 1-Year Est. Return

Opaleye Management's Q2 2016 Portfolio in Review

As of Q2 2016, Opaleye Management held 65 positions worth $150M, down 6.6% from $160M the previous quarter. Its ten largest holdings account for 46% of the portfolio.

Opaleye Management withdrew a net $11.4M in Q2 2016, closing 16 positions and reducing 12 holdings. Its most notable exit was Sage Therapeutics, an estimated $5.29M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, up from 88% a quarter earlier, followed by Miscellaneous.

Against the trend, Opaleye Management opened a new position in Horizon Therapeutics Public Limited Company Ordinary Shares worth $3.29M.

  • Opaleye Management's largest Q2 2016 buy was Horizon Therapeutics Public Limited Company Ordinary Shares: 200,000 shares worth $3.29M.
  • Opaleye Management added most to Aevi Genomic Medicine Inc in Q2 2016, an estimated $2.06M increase.
  • Opaleye Management's biggest Q2 2016 reduction was Ultragenyx Pharmaceutical, cutting an estimated $2.91M.
  • Opaleye Management fully exited Sage Therapeutics in Q2 2016, selling an estimated $5.29M.
  • Opaleye Management's ten largest holdings make up 46% of its $150M portfolio in Q2 2016.
  • Opaleye Management opened 12 new positions and closed 16 in Q2 2016.
  • Opaleye Management's portfolio value fell 6.6% quarter-over-quarter to $150M.

Based on Opaleye Management's 13F filing for Q2 2016, filed 12 Aug 2016.